İkinci doz Pfizer-BioNTech COVID-19 messenger RNA sonrası gelişen Eritema Nodozum olgusu

Year 2022, Volume: 3 Issue: 3, 322 - 323, 30.11.2022

Erdal Bodakçi

https://doi.org/10.48176/esmj.2022.94

Abstract

Erythema Nodosum (EN) is a panniculitis characterized by acute-onset inflammation of the subcutaneous fat tissue; it can be idiopathic or associated with various clinical conditions such as infections (especially Beta-hemolytic streptococcal infections), medications, pregnancy, inflammatory bowel diseases, Behçet syndrome, sarcoidosis, autoimmune diseases, and malignancies. The pathogenesis is unknown, but a delayed type IV hypersensitivity reaction to certain antigens is hypothesized [1]. EN is characterized clinically by painful tender, nodular, erythematous lesions, typically symmetrically on pretibial surfaces. The occurrence of EN after vaccination is rare and especially post-covid vaccine limited number in the literature. We describe herein, a clinical observation of EN induced by Pfizer-BioNTech COVID-19 messenger RNA vaccine.

Keywords

Eritema Nodosum, messenger RNA aşısı

Erythema Nodosum after the second dose of the Pfizer-BioNTech COVID-19 messenger RNA vaccine; a case report

Abstract

Erythema Nodosum (EN) is a panniculitis characterized by acute-onset inflammation of the subcutaneous fat tissue; it can be idiopathic or associated with various clinical conditions such as infections (especially Beta-hemolytic streptococcal infections), medications, pregnancy, inflammatory bowel diseases, Behçet syndrome, sarcoidosis, autoimmune diseases, and malignancies. The pathogenesis is unknown, but a delayed type IV hypersensitivity reaction to certain antigens is hypothesized [1]. EN is characterized clinically by painful tender, nodular, erythematous lesions, typically symmetrically on pretibial surfaces. The occurrence of EN after vaccination is rare and especially post-covid vaccine limited number in the literature. We describe herein, a clinical observation of EN induced by Pfizer-BioNTech COVID-19 messenger RNA vaccine.

Keywords

Erythema Nodosum, messenger RNA vaccine, Eritema Nodosum, haberci RNA aşısı

References

• 1. Leung AKC, Leong KF, Lam JM. Erythema nodosum.World J Pediatr2018;14: 548–554
• 2. Requena L, Sanchez Yus E. Erythema nodosum. Semin Cutan Med Surg. 2007;26(2):114–25. https://doi.org/10.1016/j. Sder.2007.02.009.
• 3. De Simone C, Caldarola G, Scaldaferri F, Petito V, Perino F, Arena V, et al. Clinical, histopathological, and immunological evaluation of a series of patients with erythema nodosum. Int J Dermatol. 2016;55(5):e289–94. https://doi.org/10.1111/ ijd.13212
• 4. Cohen PR. Combined reduced-antigen content tetanus, diphtheria,and acellular pertussis (tdap) vaccine-related erythema nodosum: case report and review of vaccine-associated erythema nodosum.DermatolTher (Heidelb). 2013;3(2):191-197.
• 5. Teymour S, Ahram A, Blackwell T, Bhate C, Cohen PJ, Whitworth JM. Erythema nodosum after Moderna mRNA-1273 COVID-19 vaccine. Dermatol Ther. 2022 Jan 4:e15302. doi: 10.1111/dth.15302. Epub ahead of print. PMID: 34984777.
• 6. Aly MH, Alshehri AA, Mohammed A, Almalki AM, Ahmed WA,Almuflihi AM, et al. First case of erythema nodosum associated with Pfizer vaccine.Cureus. 2021;13(11):e19529. doi:10.7759/cureus.19529
• 7. Wu X, Lim JHL, Lee JSS, Chio MT. Recurrent erythema nodosumafter the second dose of the Pfizer-BioNTech BNT162b2 COVID-19 messenger RNA vaccine.JAAD Int. 2022;6:107-108. doi:10.1016/j.jdin.2021.12.009
• 8. Dameska, Katerina; Simeonovskı, Viktor. Covid‐19 Vaccine Associated Erythema Nodosum: factors to consider. Dermatologic Therapy, 2022, e15410.